肺炎链球菌对大环内酯类抗生素耐药机制研究

目的了解肺炎链球菌对大环内酯类抗生素的耐药机制和转座子整合酶的流行情况。方法188株红霉素耐药肺炎链球菌，用E试验和K—B纸片扩散法检测其对11种抗菌药物的敏感性；用双纸片法（红霉素和克林霉素）确定其耐药表型；用PCR扩增这些菌株的耐药基因ermB、mefa、mefE、tetM及转座子整合酶基因intTn。结果188株红霉素耐药株中耐药基因ermB总检出率为91．5％（172／188），mefE总检出率为38．3％，未检出mefA基因。97．9Yoo的红霉素耐药株中存在转座子整合酶intTn。耐药基因组合ermB（＋）mefE（-）和ermB（＋）mef（＋），占91．5％，两者均呈cMLSB耐药表型。ermB（-）mefE（＋）占8．5％，耐药表型为M型。结论我院分离的肺炎链球菌大环内酯耐药以errnB介导的cMLS。耐药表型为主。转座子可能在本地区肺炎链球菌耐药基因的水平转移和克隆播散中起重要作用。     

肺炎链球菌红霉素相关耐药基因与耐药表型的关系

目的:了解肺炎链球菌(Streptococcuspneum oniae,SP)临床分离株红霉素耐药基因的流行状况及和耐药表型的关系。方法:对住院儿童分离到的43株肺炎链球菌进行红霉素药敏试验,并用PCR法检测与红霉素耐药相关的红霉素核糖体甲基化酶基因(ermB)、主动外排转运基因(mefA)。结果:43株肺炎链球菌红霉素药敏试验40株耐药(占93%),3株敏感。红霉素ermB基因总检出率为76.7%(33/43),mefA基因总检出率为23.3%(10/43)。3株红霉素敏感的肺炎链球菌均未检出ermB基因和mefA基因;40株红霉素耐药肺炎链球菌ermB基因和mefA基因的PCR检出率分别为82.5%(33/40)和25%(10/40)。共有35株肺炎链球菌检出ermB基因或/和mefA基因,其中单独携带ermB基因的耐药表型为25株(占71.4%);单独携带mefA基因的耐药表型2株(占5.7%);同时携带ermB基因和mefA基因的耐药表型8株(占22.9)%。结论:ermB基因和mefA基因同时表达或单独表达均可导致红霉素耐药,ermB基因表达是儿童肺炎链球菌对红霉素耐药的主要原因,mefA基因表达是造成对红霉素耐药的次要原因。红霉素已不是治疗肺炎链球菌的有效药物。     

肺炎链球菌对大环内酯类抗生素耐药及传播机制研究

目的 研究上海3所医院临床分离肺炎链球菌对大环内酯类抗生素的耐药机制及传播方式。方法收集上海市3所医院临床分离的红霉素耐药肺炎链球菌共118株，用E试验和K-B纸片扩散法检测对12种抗菌药的敏感度；用双纸片法（D试验）确定大环内酯类耐药表型；用PCR扩增检测耐药基因ermB、mefA、mefE、msrD及Tn1545-Tn916家族转座子整合酶基因intTn；用转化试验证实耐药传播方式。结果①118株肺炎链球菌对红霉素的MIC范围为4-256mg／L，其中5．9％对克林霉素敏感，对青霉素不敏感率达72．7％。左氧氟沙星、阿莫西林-克拉维酸对红霉素耐药的肺炎链球菌仍有较好的体外活性；②该组细菌耐药基因ermB检出率为88．1％，mefE、msrD检出率各为50％，未检出，mefA基因，转座子整合酶基因intTn检出率达97．5％。耐药基因组合模式以ermB（＋）reefE（＋）msrD（＋）intTn（＋）和ermB（＋）mefE（-）msrD（-）intTn（＋）为主，两者均为cMLSB型耐药。ermB（-）mefE（＋）msrD（＋）intTn（＋）模式占5．9％，耐药表型为M型。③cMLSB型耐药代表菌株ET37和M型耐药代表菌株RJ324基因组DNA均成功转化敏感株，使之表现红霉素耐药性并可传代。结论上海地区肺炎链球菌对大环内酯抗生素耐药以ermB介导的cMLSB耐药表型为主；大环内酯外排基因有流行趋势，但仅限于起源于肺炎链球菌的，mefE。耐药基因可以转化方式进行传播，转座子可能在本地区肺炎链球菌耐药基因的传播中起重要作用。     

乐清地区儿童肺炎链球菌耐药性及大环内酯类耐药表型和耐药基因型

目的：了解乐清地区儿童患者分离的肺炎链球菌耐药性及大环内酯类耐药表型和耐药基因型分布情况。方法对2014年乐清地区儿童患者分离的124株肺炎链球菌采用细菌鉴定分析仪进行9种抗菌药物的最低抑菌浓度（MIC）检测,同时对大环内酯类耐药肺炎链球菌用红霉素和克林霉素双纸片协同试验确定其耐药表型,用聚合酶链反应（PCR）扩增这些菌株的耐药基因ermB和mefE。结果124株肺炎链球菌中,红霉素、克林霉素、四环素和复方新诺明的耐药率依次为96.77％、93.55％、84.68％和81.45％;青霉素、氯霉素和左旋氧氟沙星的耐药率较低,分别为20.16％、5.65％和0.81％,未发现对阿莫西林/克拉维酸和万古霉素耐药的菌株。120株大环内酯类耐药肺炎链球菌中,大环内酯类耐药表型cMLS占96.67％、iMLS占0.83％、M型占2.50％;耐药基因ermB检出率为97.50％,mefE的检出率为6.67％。结论乐清地区儿童肺炎链球菌对大环内酯类抗生素的耐药性严重,ermB基因介导的cMLS型耐药是大环内酯类耐药的主要原因,大环内酯类抗生素已不是治疗乐清地区儿童肺炎链球菌感染的有效药物。     

肺炎链球菌对大环内酯类抗生素耐药情况及耐药基因研究

目的调查上海地区肺炎链球菌对红霉素的敏感度，研究肺炎链球菌对大环内酯类抗生素耐药机制。方法对中山医院57株临床分离肺炎链球菌进行红霉素药敏试验；应用聚合酶链反应（PCR）技术对上海4所医院中分离的53株红霉素耐药肺炎链球菌检测耐药基因（ermB，mefA，merE）。结果57株肺炎链球菌中12株（21．0％）敏感，3株（5．3％）中介，42株（73．7％）耐药。53株红霉素耐药肺炎链球菌中，ermB基因、mere基因、mefA基因分别在51株（96．2％）、22株（41．5％）和1株（1．9％）中检测到。其中21株（39．6％）同时检测到ermB基因和mefE基因，1株（1．9％）同时检测到ermB基因和mefA基因，1株（1．9％）未检测到ermB基因、mefE基因或mefA基因。结论上海地区肺炎链球菌对大环内酯类抗生素耐药率较高。ErmB介导的靶位改变是最常见的耐药机制，mef（特别是mefE）介导外排机制引起者也较常见。     

肺炎链球菌对抗菌药物的耐药性调查及对大环内酯类抗生素耐药机制研究

目的：调查成都地区肺炎链球菌对抗菌药物的敏感性，研究成都地区肺炎链球菌对大环内酯类抗生素耐药机制。方法：收集2001年9月-2002年9月成都地区临床分离的肺炎链球菌，测定其对13种抗菌药物的耐药性及对大环内酯类抗生素的耐药表型；用聚合酶链反应(PCR)扩增耐药基因ermB和mefA，并对ermB和mefA进行基因序列分析。结果：82株肺炎链球菌中13株对青霉素低度耐药(占15．9％),肺炎链球菌对大环内酯类抗生素和克林霉素表现出较高的耐药率，对红霉素和克林霉素耐药率分别为80．5％(66／82)和68．3％(56／82)。耐大环内酯类肺炎链球菌中,96．4％菌株表现为内在型耐药。标准菌株ATCC49619及16株红霉素敏感菌株均未检测到ermB基因及mefA基因；ermB基因和；mefA基因分别在62和11株耐红霉素肺炎链球菌中检测到，其中7株菌同时检测到ermB基因和mefA基因。所测ermB和mefA基因序列与基因库收录序列高度一致。结论：成都地区临床分离的肺炎链球菌对青霉素耐药率较低，但对大环内酯类抗生素和克林霉素耐药却非常普遍。ermB基因介导的靶位改变是成都地区肺炎链球菌对大环内酯类抗生素的主要耐药机制。     

肺炎链球菌对大环内酯-林可酰胺-链阳菌素的耐药监测及耐药机制研究

目的研究肺炎链球菌对大环内酯-林可酰胺-链阳菌素类抗菌素的耐药机制。方法K-B纸片法测定肺炎链球菌对红霉素、克林霉素、泰利霉素和喹奴普汀/达福普汀的耐药性。对全部红霉素耐药菌株和部分红霉素敏感菌株用聚合酶链反应(PCR)检测ermB和mefA基因。结果97株肺炎链球菌对红霉素、克林霉素、泰利霉素和喹奴普汀/达福普汀的耐药率分别为60.8%、58.8%、0和0。59株红霉素耐药菌株均检出ermB和/或mefA基因,其中34株(57.6%)ermB阳性,18株(30.5%)ermB和mefA同时阳性,7株(11.8%)mefA阳性。5株敏感菌株ermB和mefA基因均为阴性。结论本研究显示肺炎链球菌对泰利霉素和喹奴普汀/达福普汀高度敏感,而对红霉素和林可霉素则表现出较高的耐药性。肺炎链球菌对大环内酯-林可酰胺-链阳菌素的耐药机制以ermB基因介导的靶位改变为主。     

儿童鼻咽部肺炎链球菌携带株研究

目的了解武汉地区健康儿童肺炎链球菌带菌状况、耐药性、耐药基因及血清型流行情况。方法收集武汉地区2所幼儿园469名健康儿童的鼻咽拭子标本,分离鉴定肺炎链球菌,琼脂稀释法测定其对12种抗菌药物的MIC;PCR检测红霉素耐药基因ermB和mefA;“荚膜肿胀”试验进行血清学分型。结果469份鼻咽拭子标本共分离出116株肺炎链球菌,分离率为24.7%。存活的114株中,肺炎链球菌对青霉素的敏感率为51.8%(59/114),对红霉素的敏感率为13.2%(15/114)。99株红霉素耐药肺炎链球菌中,ermB基因总检出率为98.0%(97/99),其中30株(31.6%)同时具有ermB和mefA基因,2株红霉素低耐株仅检出mefA基因。血清分型涉及16个血清型、群,主要分布在19、23、6和14血清群。结论武汉地区肺炎链球菌耐药性高,多为多重耐药菌株,红霉素耐药基因主要为ermB,19、23、6血清群多重耐药株分布广泛。     

肺炎链球菌大环内酯类抗生素的耐药性分析

目的本研究通过对肺炎链球菌耐药表型检测分析,掌握本地区肺炎链球菌耐药的现状和趋势。方法本文用E试验和K-B纸片扩散法检测84株肺炎链球菌临床分离株对9种抗生素的敏感性;用双纸片法确定大环内酯类耐药表型。结果84株肺炎链球菌红霉素耐药占85.7%(72/84),对青霉素不敏感率达57.1%(48/84)。左氧氟沙星、阿莫西林/克拉维酸对该组细菌有较好的体外活性,敏感率分别为83.3%(70/84)和88.1%(74/84)。结论肺炎链球菌对大环内酯耐药严重,且表现对四环素、复方磺胺甲噁唑、青霉素等多重耐药;南昌地区大环内酯类耐药表型主要以cMLSB为主。     

β溶血链球菌中诱导型克林霉素耐药的检测和分析

目的 了解β溶血链球菌对红霉素及克林霉素的耐药性,探讨红霉素对克林霉素诱导耐药的表型和基因型.方法 按CLSI推荐的K-B法测定并判读β溶血链球菌对红霉素及克林霉素的耐药性,用D试验检测红霉素诱导β溶血链球菌对克林霉素耐药的表型,并且用PCR方法确定所检测的菌株是否携带的ermB基因和mefA基因.结果 49株红霉素耐药的β溶血链球菌结果显示有35株β溶血链球菌只扩增到ermB基因,有9株只扩增到mefA基因,有3株同时扩增到ermB和mefA基因,有2株没有扩增到ermB和或mefA基因;17株红霉素耐药克林霉素敏感菌株中D试验阳性8株细菌都只扩增到ermB,D试验阴性9株细菌中都只扩增到mefA;红霉素敏感的β溶血链球菌没有扩增到ermB或mefA基因.结论 β溶血链球菌的耐药表型与基因型高度一致,临床上可用PCR方法和D试验检测,D试验检测更为简单方便,临床应该用D试验检测β溶血链球菌的iMLS型耐药.     

Gefitinib reverses breast cancer resistance protein-mediated drug resistance

Breast cancer resistance protein (BCRP) is an ATP binding cassette transporter that confers resistance to a series of anticancer agents such as 7-ethyl-10-hydroxycamptothecin (SN-38), topotecan, and mitoxantrone. In this study, we evaluated the possible interaction of gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor, with BCRP. BCRP-transduced human epidermoid carcinoma A431 (A431/BCRP) cells acquired cellular resistance to gefitinib, suggesting that BCRP could be one of the determinants of gefitinib sensitivity in a certain sort of cells. Next, the effect of gefitinib on BCRP-mediated drug resistance was examined. Gefitinib reversed SN-38 resistance in BCRP-transduced human myelogenous leukemia K562 (K562/BCRP) or BCRP-transduced murine lymphocytic leukemia P388 (P388/BCRP) cells but not in these parental cells. In addition, gefitinib sensitized human colon cancer HT-29 cells, which endogenously express BCRP, to SN-38. Gefitinib increased intracellular accumulation of topotecan in K562/BCRP cells and suppressed ATP-dependent transport of estrone 3-sulfate, a substrate of BCRP, in membrane vesicles from K562/BCRP cells. These results suggest that gefitinib may overcome BCRP-mediated drug resistance by inhibiting the pump function of BCRP. Furthermore, P388/BCRP-transplanted mice treated with combination of irinotecan and gefitinib survived significantly longer than those treated with irinotecan alone or gefitinib alone. In conclusion, gefitinib is shown to interact with BCRP. BCRP expression in a certain sort of cells is supposed to be one of the determinants of gefitinib sensitivity. Gefitinib inhibits the transporter function of BCRP and reverses BCRP-mediated drug resistance both in vitro and in vivo.     

Gentamicin resistance in Pseudomonas aeruginosa: R-factor-mediated resistance

By disk diffusion antimicrobial susceptibility testing, 11% of 313 consecutive strains of Pseudomonas aeruginosa, examined during July to October 1973, were resistant to gentamicin (minimal inhibitory concentration 12.5 to >100 mug/ml), and a further 31% were moderately resistant (6.25 to 12.5 mug/ml) to gentamicin at the University of Alberta Hospital in Edmonton, Canada. Of 45 gentamicin-resistant strains from that hospital, none possessed R-factors or gentamicin-inactivating enzymes. Eight of 13 strains obtained from three American sources, which contained gentamicin-acetylating (12 strains) or -adenylating (1 strain) activity, conjugally transferred both gentamicin resistance and antibiotic-inactivating activity. P. aeruginosa recipients were much more effective for detection of transferable gentamicin resistance than Escherichia coli recipients, although not all P. aeruginosa were equally as effective as recipients. One strain, POW 151, transferred resistance to both carbenicillin and gentamicin as well as to several other antibiotics. R-factors detected belonged to P-2 and P-3 (Com 6, C) incompatibility groups. Expression of gentamicin resistance due to acetylation of gentamicin was subject to marked phenotypic lag, especially in recipient strain P. aeruginosa 280. This was shown to result in the failure to detect gentamicin resistance transfer if the concentration of gentamicin in selection media was too high (>2.5 mug/ml for strain 280). Some but not all recipients were changed in pyocine type upon acquisition of R-factors.     

Insulin resistance

Insulin resistance is closely associated with fat accumulation in liver. Thus, it has been suggested that insulin resistance is one of the important factor in development of non-alcoholic steatohepatitis(NASH). For example, insulin resistance in adipocyte results in increased lipolysis and delivery of free fatty acids(FFAs) to the liver, which induce fatty liver. If there is insulin resistance in skeletal muscle, hyperinsulinemia and/or hyperglycemia might increase fat accumulation in liver, through, at least in part, increased sterol-regulatory element binding protein-1c(SREBP-1c) activation. However, hepatic insulin resistance might prevent fat accumulation in liver, because insulin strongly induces lipogenesis. Thus, the tissue specific insulin resistance should be considered in the pathogenesis of NASH.     

Aspirin resistance

OBJECTIVE: To review the literature addressing the problem of aspirin resistance in patients with vascular disease. DATA SOURCES: A MEDLINE search (1966-February 2002) was performed. Key search terms included aspirin, resistance, resistant, failure, tolerance, and nonresponder. English-language studies were identified as well as pertinent references from these articles. DATA SYNTHESIS: Aspirin resistance has been reported in patients with cardiovascular, cerebrovascular, and peripheral vascular disease. Because of differences in the definition of resistance, variations in detection methods, and a lack of controlled trials, the true significance of the problem remains unknown. Multiple mechanisms for resistance have been proposed, including increased reactivity to platelet aggregating factors, genetic polymorphism, and alternate pathways for thromboxane synthesis. The studies to date have failed to demonstrate consistent relationships between aspirin's platelet-inhibiting effects, the impact of dosage escalation, and clinical outcomes. CONCLUSIONS: For many patients, aspirin is an effective antithrombotic agent. However, patients taking aspirin may demonstrate highly variable responses to in vitro tests for platelet aggregation and may experience breakthrough thromboembolic events. Although this phenomenon has been termed aspirin resistance, the lack of a uniform definition or agreement on diagnostic criteria precludes definitive recommendations at this time. In addition, strategies are needed to identify patients at risk for aspirin resistance who might benefit from alternative or combined antiplatelet therapy.     

Antibiotic resistance

Resistance to antibiotics is economically and physiologically costly. Control of antibiotic resistance will require aggressive implementation of numerous strategies. Ongoing surveillance is needed to monitor known antibiotic types and to be able to identify the development of other potential types. Early intervention is needed to combat the rising rate of resistance. Persistent use of hygiene measures and controlled use of antibiotics will limit the spread of antibiotic resistance. Health care providers need to monitor adherence to control measures. Hand and environmental control measures remain a critical component of staff education activities. Active management of infections with non-pharmacologic treatments should be promoted. Motivational campaigns will reinforce positive infection control behaviors. Consistent surveillance of antibiotic use will help fulfill the CDC directive to combat antibiotic resistance and keep the population healthy.     

Insulin resistance

There are several mechanisms about high blood pressure induced by insulin resistance in type 2 diabetes. Hyperinsulinemia is rare in Japanese type 2 diabetic patients. Therefore, hyperinsulinemia is not a major cause of high blood pressure in Japanese type 2 diabetic patients. Diabetic nephropathy was associated with high blood pressure. There was a relation between diabetic nephropathy and insulin resistance. Coexistence of essential hypertension with type 2 diabetes. Both essential hypertension and type 2 diabetes were related with insulin resistance. Vascular endothelial dysfunction was associated with insulin resistance. High blood pressure was partially caused by the endothelial dysfunction. The degree of insulin induced vasodilation was reduced in the type 2 diabetic patients with insulin resistance.